Seeking Alpha

AstraZeneca (AZN +0.3%) says results from its PLATO study of a greater reduction in thrombotic...

AstraZeneca (AZN +0.3%) says results from its PLATO study of a greater reduction in thrombotic cardiovascular events with Brilinta tablets plus aspirin compared to clopidogrel plus aspirin were consistent regardless of age. The data is now published in the September issue of Circulation: Cardiovascular Quality and Outcomes, and were presented at the American College of Cardiology.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector